Good Clinical Response in a Rare Aggressive Hematopoietic Neoplasm: Plasmacytoid Dendritic Cell Leukemia with No Cutaneous Lesions Responding to 4 Donor Lymphocyte Infusions Following TransplantReportar como inadecuado




Good Clinical Response in a Rare Aggressive Hematopoietic Neoplasm: Plasmacytoid Dendritic Cell Leukemia with No Cutaneous Lesions Responding to 4 Donor Lymphocyte Infusions Following Transplant - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Case Reports in TransplantationVolume 2011 2011, Article ID 651906, 4 pages

Case Report

Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA

Division of Hematology-Oncology, Mount Sinai Medical Center, 1425 Madison Avenue, New York City, NY 10029, USA

Received 24 August 2011; Accepted 18 September 2011

Academic Editors: M. G. H. Betjes and M. Sadeghi

Copyright © 2011 Amir Steinberg et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Blastic Plasmacytoid Dendritic Cell Neoplasm BPDCN is a rare and aggressive malignancy that usually presents with diffuse cutaneous lesions. While a favorable response to therapy occurs in a majority of cases, a sustained long-term response is uncommon. Most patients subsequently relapse within a year. In the following report, we present the case of a 41-year-old woman who has not displayed many of the clinical features traditionally associated with BPDCN. The patient received sporadic chemotherapy treatment over the course of 2 years, before undergoing an allogeneic stem cell transplant. Although she ultimately relapsed following her transplant, her disease has repeatedly returned into remission after donor lymphocyte infusion DLI. Currently, the patient is in remission following her fourth DLI. We believe that allogeneic transplantation should be considered as front-line therapy for the treatment of this rare malignancy.





Autor: Amir Steinberg, Rina Kansal, Matthew Wong, Angela Lopez, Stephen Lim, Jean Lopategui, and Michael Lill

Fuente: https://www.hindawi.com/



DESCARGAR PDF




Documentos relacionados